Connor Clark & Lunn Investment Management Ltd. increased its position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 23.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 223,569 shares of the medical device company's stock after purchasing an additional 41,847 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.45% of AtriCure worth $7,212,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently made changes to their positions in the company. LPL Financial LLC grew its stake in shares of AtriCure by 5.4% in the 4th quarter. LPL Financial LLC now owns 11,465 shares of the medical device company's stock worth $350,000 after buying an additional 584 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of AtriCure by 43.1% in the 4th quarter. JPMorgan Chase & Co. now owns 365,183 shares of the medical device company's stock worth $11,160,000 after buying an additional 110,039 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of AtriCure by 8.5% in the 4th quarter. Russell Investments Group Ltd. now owns 156,649 shares of the medical device company's stock worth $4,787,000 after buying an additional 12,212 shares during the last quarter. Invesco Ltd. grew its stake in shares of AtriCure by 0.8% in the 4th quarter. Invesco Ltd. now owns 43,647 shares of the medical device company's stock worth $1,334,000 after buying an additional 334 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in AtriCure by 67.1% during the 4th quarter. Renaissance Technologies LLC now owns 163,900 shares of the medical device company's stock valued at $5,009,000 after purchasing an additional 65,800 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.
Insider Activity
In other news, Director Regina E. Groves sold 2,452 shares of AtriCure stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $36.82, for a total value of $90,282.64. Following the sale, the director directly owned 33,715 shares of the company's stock, valued at approximately $1,241,386.30. The trade was a 6.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Vinayak Doraiswamy sold 2,500 shares of AtriCure stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $36.58, for a total value of $91,450.00. Following the completion of the sale, the insider directly owned 71,872 shares in the company, valued at $2,629,077.76. This trade represents a 3.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 7,452 shares of company stock worth $265,333 over the last 90 days. Company insiders own 3.50% of the company's stock.
AtriCure Stock Performance
NASDAQ ATRC traded down $1.29 on Thursday, hitting $35.41. 387,667 shares of the company traded hands, compared to its average volume of 591,228. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -45.99 and a beta of 1.61. The company has a current ratio of 3.94, a quick ratio of 2.83 and a debt-to-equity ratio of 0.16. The business's 50 day moving average price is $32.71 and its 200-day moving average price is $34.16. AtriCure, Inc. has a 52-week low of $22.81 and a 52-week high of $43.11.
AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The medical device company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.13. AtriCure had a negative return on equity of 4.20% and a negative net margin of 7.27%. The business had revenue of $136.14 million for the quarter, compared to the consensus estimate of $130.17 million. During the same period in the previous year, the business earned ($0.17) earnings per share. The business's revenue was up 17.1% on a year-over-year basis. Equities analysts expect that AtriCure, Inc. will post -0.6 earnings per share for the current year.
Wall Street Analyst Weigh In
Several analysts have commented on the company. Wall Street Zen upgraded AtriCure from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Needham & Company LLC increased their target price on AtriCure from $44.00 to $45.00 and gave the company a "buy" rating in a research note on Wednesday, July 30th. JMP Securities reiterated a "market outperform" rating and set a $60.00 target price on shares of AtriCure in a research note on Wednesday, April 30th. UBS Group cut their target price on AtriCure from $60.00 to $58.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Finally, BTIG Research set a $54.00 target price on AtriCure in a research note on Wednesday, July 30th. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $50.89.
Check Out Our Latest Report on AtriCure
AtriCure Profile
(
Free Report)
AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
Featured Stories

Before you consider AtriCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AtriCure wasn't on the list.
While AtriCure currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.